Muscarinic receptor ligands and their therapeutic potential.
about
M1 receptors mediate cholinergic modulation of excitability in neocortical pyramidal neurons.Muscarinic agonists for the treatment of cognition in schizophreniaMultiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtypeM4 muscarinic receptor knockout mice display abnormal social behavior and decreased prepulse inhibition.Synthesis and SAR of selective muscarinic acetylcholine receptor subtype 1 (M1 mAChR) antagonists.Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I: Exploration of alternative benzyl and privileged structure moietiesSynthesis and SAR of analogs of the M1 allosteric agonist TBPB. Part II: Amides, sulfonamides and ureas--the effect of capping the distal basic piperidine nitrogen.Chemical genomics: massively parallel technologies for rapid lead identification and target validation.Synthesis and SAR of N-(4-(4-alklylpiperazin-1-yl)phenyl)benzamides as muscarinic acetylcholine receptor subtype 1 (M1) anatgonists.Spontaneous phasic activity of the pig urinary bladder smooth muscle: characteristics and sensitivity to potassium channel modulatorsHydroxycinnamic acid amides from Scopolia tangutica inhibit the activity of M1 muscarinic acetylcholine receptor in vitro.Intact attentional processing but abnormal responding in M1 muscarinic receptor-deficient mice using an automated touchscreen method.M5 receptor activation produces opposing physiological outcomes in dopamine neurons depending on the receptor's locationSelective targeting of G-protein-coupled receptor subtypes with venom peptides.The recent progress in research on effects of anesthetics and analgesics on G protein-coupled receptors.New pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors.Employing novel animal models in the design of clinically efficacious GPCR ligands.Clinical potential of aclidinium bromide in chronic obstructive pulmonary diseasePharmacological models in Alzheimer's disease researchEffects of norepinephrine and acetylcholine on the development of cultured Leydig cells in mice.Molecular conversion of muscarinic acetylcholine receptor M(5) to muscarinic toxin 7 (MT7)-binding protein.Contrasting effects of allosteric and orthosteric agonists on m1 muscarinic acetylcholine receptor internalization and down-regulation.Microscopic binding of M5 muscarinic acetylcholine receptor with antagonists by homology modeling, molecular docking, and molecular dynamics simulationRole of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity.A pH-sensitive potassium conductance (TASK) and its function in the murine gastrointestinal tract.Relaxant action mechanism of berberine identified as the active principle of Argemone ochroleuca Sweet in guinea-pig tracheal smooth muscle.Stereoselectivity of satropane, a novel tropane analog, on iris muscarinic receptor activation and intraocular hypotension.
P2860
Q24653082-9DBB80FB-F1B9-47AB-9507-2504AB61D72FQ28301970-47E15052-6D2D-467E-849A-7036C789290EQ28591691-1BC65903-C8B0-44D3-B1CD-F1AF351DB79EQ30467341-79FD040C-CDC0-4A2A-B1CE-4CBE7B410B3FQ33313445-34A58781-9CFC-4AE2-B686-ECEC8027AF11Q33370832-CEA599E6-D0DF-4E2F-BCB9-AC19F5CDB035Q33373225-1EC8E86B-7A5E-49C2-82CC-CCC475234A1FQ33383932-AD0A2916-2C00-4EA2-B360-6C4B636F40B0Q33536927-83EDD055-F88D-40B1-9150-33975D56BCAFQ35044074-CCB5C88D-28D0-4936-B836-04FB69DC639CQ36421337-CD6BAB8B-2259-4722-80E8-AD0A6AD11684Q37506679-1B09ED1B-F114-4C47-8FC6-0F7BBA145B86Q37603769-D1191EF1-8733-4CBA-8F2A-76527A59B5D7Q37863750-F617DFC8-2A64-4AF5-98AD-B081E8455B8FQ38055664-5807DBBC-6433-40DB-9521-BCD619992BC8Q38099889-57E1AEAE-2137-407F-AA0A-04A9CE85348CQ38200338-88D43C12-757D-4B5A-81DD-1EE1DC920822Q38223379-67B9DA35-D22E-49EE-9C86-69F9071FFA85Q38578433-97B8FEAA-DA1B-4B91-8E04-F4143FD457A7Q39254211-D887F974-2D09-4838-A7A6-F48E7D00436AQ39765332-2BD5101F-7F35-4FE6-90DE-95E03BB716FBQ39797234-E0CEF74D-2CC4-4C17-81FB-77E09216EB11Q40370946-98A77DE8-53E8-4C6B-B793-FF6154A9A129Q44416460-904DC635-BF25-49C8-B5D4-E0B5F85EB227Q46387182-8148AEE0-6A4F-4D5A-B002-C731870AAB76Q46780469-4A794AAC-E8B9-40EE-BB79-F5B76769048BQ46794524-054D5C21-C565-4D16-A1C4-0F661E94AACC
P2860
Muscarinic receptor ligands and their therapeutic potential.
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Muscarinic receptor ligands and their therapeutic potential.
@ast
Muscarinic receptor ligands and their therapeutic potential.
@en
type
label
Muscarinic receptor ligands and their therapeutic potential.
@ast
Muscarinic receptor ligands and their therapeutic potential.
@en
prefLabel
Muscarinic receptor ligands and their therapeutic potential.
@ast
Muscarinic receptor ligands and their therapeutic potential.
@en
P2093
P1476
Muscarinic receptor ligands and their therapeutic potential.
@en
P2093
P304
P356
10.1016/S1367-5931(99)80063-5
P577
1999-08-01T00:00:00Z